ICU Medical (ICUI) Following Raised 2026 Guidance Looks Modestly Undervalued
ICU Medical (ICUI) raised its 2026 earnings guidance after releasing second quarter results on 6 August 2026, indicating higher expected GAAP net income and diluted EPS for the full year.
See our latest analysis for ICU Medical.
ICU Medical’s latest guidance hike comes after a strong run in the stock, with a 30 day share price return of 18.13% and a 1 year total shareholder return of 68.75%. This suggests momentum has been building as investors reassess growth potential and risk.
If this kind of earnings driven move has your attention, it could be a good moment to scan other healthcare technology opportunities using our 43 healthcare AI stocks
ICU Medical has already enjoyed a strong rerating on the back of upgraded 2026 guidance and a sharp share price move. The next step is to ask whether the current valuation still leaves meaningful upside on the table.
Most Popular Narrative: 4.7% Undervalued
Analysts following ICU Medical see a fair value of $191.50 per share, slightly above the last close at $182.42, which frames the current upside case.
The ongoing global increase in healthcare utilization, particularly due to an aging population and rising rates of chronic diseases, is driving steady, structural growth in demand for infusion therapies and consumables, ICU Medical's largest segment, which just experienced record sales and is expected to see continued sequential growth, positive impact on long-term revenue.
Want to see what sits behind that fair value gap for ICU Medical? The narrative leans on a mix of top line expansion, rising margins, and a richer earnings profile over time.
Result: Fair Value of $191.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ICU Medical’s story can change quickly if tariff pressures on manufacturing deepen or regulatory issues around recalls and product clearances start to have a greater impact.
Find out about the key risks to this ICU Medical narrative.
Another View On ICU Medical’s Valuation
The earlier narrative pointed to a fair value of $191.50 per ICU Medical share based on analyst assumptions. Our DCF model takes a different angle and points to a value of $211.45 per share, which is higher than both the current $182.42 price and the analyst target.
This suggests that the DCF view indicates more potential upside compared with the analyst target, while the recent share price movement has already closed part of the gap. The key question for you is whether the cash flow path implied in the DCF appears realistic enough to rely on.
Look into how the SWS DCF model arrives at its fair value.
Next Steps
With ICU Medical drawing both concern and optimism, now is a good time to look through the numbers yourself, weigh the risks and rewards, and decide what matters most to your portfolio by checking the 3 key rewards and 3 important warning signs
Looking for more investment ideas beyond ICU Medical?
If ICU Medical has sharpened your focus, now is the moment to widen your watchlist with fresh ideas that could suit different goals, risk levels, and timeframes.
- Target steady compounding potential by reviewing companies screened for quality and attractive pricing through the 52 high quality undervalued stocks.
- Prioritize resilience by scanning stocks that pass strict balance sheet and fundamentals checks using the solid balance sheet and fundamentals stocks screener (48 results).
- Spot under-the-radar potential by sorting through a screener containing 21 high quality undiscovered gems that many investors may not be watching yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com